clinical research prime

Kids & Teens CMV Vaccine Study

  • A Phase 1/2a, Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine.
  • Males and Females ages 9-15 years old.
  • Participants will also receive study related treatment at no cost and will be compensated for time and travel.